skip to Main Content

At Maverick Therapeutics, we are developing the most advanced T cell engaging platform in its class, aiming to offer patients an extended duration and enhanced quality of life. Our approach begins by identifying the challenge of current bispecific antibodies beyond hematological cancers.

  • With a limited therapeutic window, T cell therapies have yet to show promise in solid tumor cancers, which represent 90% of all cancer diagnoses, translating to approximately 1.5 million diagnoses per year. 1
  • Immune checkpoint inhibitors have rightly been hailed as a major breakthrough for patients, but with average overall response rates ranging from 0-24% in select solid tumor indications 2, there is room for improvement in providing patients with more treatment options with higher response rates.

COBRATM Therapeutic Platform

The COBRA™ platform addresses these challenges by activating T cells and initiating tumor killing only at the site of the tumor. Unlike other bispecific T cell engagers that are inherently active and potent when administered, each COBRA™ therapy is designed to bind to a specific target and engineered to be an inactive prodrug until it enters the tumor microenvironment.

COBRA™ molecules also include a component that extends their half-life in circulation prior to activation, which allows for less frequent dosing versus the patient-unfriendly continuous infusion required for first generation T cell engagers. Once activated within the tumor microenvironment, this half-life extension component is physically detached, allowing for rapid elimination of the active molecules after they’ve killed the cancer cells, further improving the safety window by reducing the chance that an activated COBRA™ molecule will travel to nearby healthy tissues and cause damage.

References

  1. Cancer Classification | SEER Training. (2019). Retrieved from https://training.seer.cancer.gov/disease/categories/classification.html
  2. Based on efficacy data in the Prescribing Information for each therapy listed: breast, lung, prostate, colorectal, melanoma, uterine & ovarian, kidney & renal, head & neck, pancreas
Back To Top